Jennifer Graham

ORCID: 0000-0002-8538-0449
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Intraperitoneal and Appendiceal Malignancies
  • Oral and Maxillofacial Pathology
  • Genetic factors in colorectal cancer
  • Cutaneous Melanoma Detection and Management
  • Ovarian cancer diagnosis and treatment
  • Evolution and Genetic Dynamics
  • Distributed and Parallel Computing Systems
  • Endometriosis Research and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Genomics and Rare Diseases
  • Periodontal Regeneration and Treatments
  • Microfluidic and Bio-sensing Technologies
  • Privacy-Preserving Technologies in Data
  • Oral and gingival health research
  • Single-cell and spatial transcriptomics
  • Nonmelanoma Skin Cancer Studies
  • Lymphoma Diagnosis and Treatment
  • Cancer-related molecular mechanisms research
  • Oral Health Pathology and Treatment
  • Molecular Biology Techniques and Applications
  • Scientific Computing and Data Management

University of Detroit Mercy
2024

Molecular Oncology (United States)
2020-2021

Fusion Academy
2021

Fusion (United States)
2021

Wellcome Sanger Institute
2018-2019

St James's University Hospital
2015-2017

Leeds Teaching Hospitals NHS Trust
2016

Wellcome Trust
2015

It is frequently assumed that pre-invasive lesions are simpler precursors of cancer and will contain a limited subset the genomic changes seen in their associated invasive disease. Driver mutations thought to occur early, but it not known how many these present lesions. These assumptions need be tested with increasing focus on both personalised treatments early detection methodologies. We examined copy number 256 samples from 69 oral patients. Forty-eight 16 patients were further using exome...

10.1186/s13073-017-0442-0 article EN cc-by Genome Medicine 2017-06-07

// Caroline Conway 1, 2 , Jennifer L. Graham 1 Preetha Chengot Catherine Daly Rebecca Chalkley Lisa Ross Alastair Droop Pamela Rabbitts Lucy F. Stead Precancer Genomics, Leeds Institute of Cancer and Pathology, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK Stratified Medicine (Oncology), School Biomedical Sciences, Ulster, Coleraine, Co. Londonderry, BT52 1SA, Correspondence to: Stead, e-mail: l.f.stead@leeds.ac.uk Keywords: RNAseq, oral squamous cell...

10.18632/oncotarget.5529 article EN Oncotarget 2015-10-19

The study of the relationships between pre-cancer and cancer identification early driver mutations is becoming increasingly important as value molecular markers disease personalised drug targets recognized, especially now extent clonal heterogeneity in fully invasive being realized. It has been assumed that pre-cancerous lesions exhibit a fairly passive progression to disease; degree which they, too, are heterogeneous unknown. We performed ultra-deep sequencing thousands selected mutations,...

10.1002/path.4576 article EN The Journal of Pathology 2015-06-19

The use of the DNA dyes Hoechst (HO) and chromomycin A3 (CA3) has become preferred combination for bivariate analysis chromosomes from both human animals. This requires a flow cytometer equipped with lasers specific wavelength higher power than is typical on conventional bench top cytometer. In this study, we have investigated resolution chromosome peaks in cell line normal karyotype using different combinations number cytometers available cytometry core facility. Chromosomes were prepared...

10.1002/cyto.a.23692 article EN cc-by Cytometry Part A 2018-12-17

Identification of genomic mutations by molecular testing plays an important role in diagnosis, prognosis, and treatment myeloid neoplasms. Next-generation sequencing (NGS) is efficient method for simultaneous detection clinically significant with high sensitivity. Various NGS based in-house developed commercial neoplasm panels have been integrated into routine clinical practice. However, some genes frequently mutated malignancies are particularly difficult to sequence (e.g., CEBPA , CARL...

10.1371/journal.pone.0243683 article EN cc-by PLoS ONE 2021-04-28

Abstract Identification of genomic mutations by molecular testing plays an important role in diagnosis, prognosis, and treatment myeloid neoplasms. Next-generation sequencing (NGS) is efficient method for simultaneous detection clinically significant with high sensitivity. However, due to lack standard NGS protocols, the application hematologic malignancies into clinical settings remains limited. We report development validation a 48-gene panel profiling neoplasms including acute leukemia...

10.1101/2020.11.30.403634 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2020-11-30

Shared resource laboratories (SRLs) offer instrumentation, training, and support to investigators play an important role in the progress development of science. To facilitate daily tasks provide effective service, we have made use computer scripts; a list commands that are processed sequentially, automate our flow cytometry facility. Using Python application programming interface (API), user communication produce schedule display screen. We exploit accessible nature open standards R analyze...

10.1002/cyto.a.23775 article EN cc-by Cytometry Part A 2019-04-29

Abstract Background: Identification of genomic variants by molecular testing plays an important role in classification, risk stratification, and management myeloid neoplasms. Next-generation sequencing (NGS) assays that target frequently mutated genes are commonly used clinical settings. Owing to the complexity NGS workflow, performance requirements each assay must be validated for intended use. However, scarcity optimal validation samples challenges efficient assays. We previously reported...

10.1158/1538-7445.am2020-5742 article EN Cancer Research 2020-08-15
Coming Soon ...